Zobrazeno 1 - 10
of 106
pro vyhledávání: '"David, Paling"'
Autor:
Nevin John, Jeremy Chataway, Jacqueline Palace, Gavin Giovannoni, David Paling, Frederik Barkhof, Floriana De Angelis, Lorraine Smith, Thomas Williams, Martin Duddy, James Overell, Basil Sharrack, Sebastien Ourselin, Allan Walker, Siddharthan Chandran, Richard Nicholas, Shuna Colville, Peter Connick, Carolyn Young, Jeremy Hobart, Anisha Doshi, Sharmilee Gnanapavan, Helen Ford, Baljean Dhillon, Thanh Phan, Arman Eshaghi, Julia Aram, Nigel Stallard, James Cameron, Brendan McLean, Matthew Craner, Domenico Plantone, Jonathan Stutters, Ferran Prados Carrasco, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Clive Hawkins, Roger Bastow, Daisy Mollison, Waqar Rashid, Joe Guadagno, Nikolaos Evangelou, Seema Kalra, Alberto Calvi, Yingtong Li, Tiggy Beyene, Vanessa Bassan, Alvin Zapata, Dawn Lyle, Heinke Arndt
Publikováno v:
BMJ Neurology Open, Vol 6, Iss 2 (2024)
Background The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced p
Externí odkaz:
https://doaj.org/article/03779c5cc9264a67966bb74f4a5ef24d
Autor:
Stephen L. Hauser, Ludwig Kappos, Amit Bar-Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, Roseanne Sullivan, Gordon Graham, Martin Merschhemke, Dieter A. Häring, Patrick Vermersch
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1491-1515 (2023)
Abstract The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for
Externí odkaz:
https://doaj.org/article/eebd67c7598744dda6a94266f7a71dd5
Autor:
Gavin Giovannoni, Stephen J Walters, David Paling, Olga Ciccarelli, Cindy Cooper, Eli Silber, Martin Duddy, Hannah Hunter, David Hunt, Basil Sharrack, Paul Gallagher, Ian Galea, Richard Nicholas, Annalena Venneri, Neil Robertson, Carolyn Young, Jeremy Hobart, David Rog, Ben Turner, Muhammad Saif, Azza Ismail, Gavin Brittain, John A Snowden, Diana Papaioannou, Alasdair J Coles, Gordon Mazibrada, Neil Scolding, Maruthi Vinjam, Matthew Bursnall, Claire Rice, Ian Pomeroy, Majid Kazmi, Esmaeil Nikfekr, Kim Orchard, Thushan de Silva, Jennifer Petrie, Elisa Roldan, Caroline Besley, Kate E M Duffy, Rachel Glover, Katie Hullock, Colette Beecher, Ian Gabriel, Charalampia Kyriakou, Andy Peniket, Paolo A Muraro, Amy Publicover, Andy Clark, Charles Crawley, Eleni Tholouli, Fran Kinsella, Gabriele De Luca, Jeff Davies, Jenny Byrne, Keith Campbell, Leonora Finisku, Simon Bulley, Vic Campbell
Publikováno v:
BMJ Open, Vol 14, Iss 2 (2024)
Introduction Autologous haematopoietic stem cell transplantation (aHSCT) is increasingly used as treatment for patients with active multiple sclerosis (MS), typically after failure of disease-modifying therapies (DMTs). A recent phase III trial, ‘M
Externí odkaz:
https://doaj.org/article/cef35258b9e74bbbaf15d925d8681e1d
Autor:
Riccardo Manca, Micaela Mitolo, Iain D Wilkinson, David Paling, Basil Sharrack, Annalena Venneri
Publikováno v:
Neural Regeneration Research, Vol 16, Iss 6, Pp 1111-1120 (2021)
Cognitive impairments are commonly observed in patients with multiple sclerosis and are associated with lower levels of quality of life. No consensus has been reached on how to tackle effectively cognitive decline in this clinical population non-phar
Externí odkaz:
https://doaj.org/article/12c361f221cd4f33bc0b227d27a1b8c3
Autor:
David Paling, Basil Sharrack, Joyutpal Das, Kathleen Baster, Chayaporn Chotiyarnwong, Krishnan Nair, Lorenza Angelini, Ellen Buckley, Claudia Mazza, Daniel Heyes, Ridha Ramiz, Azza Ismail, Ali Ali, Ralf Lindert, Sian Price
Publikováno v:
BMJ Neurology Open, Vol 2, Iss 1 (2020)
Background Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals.Objective Thi
Externí odkaz:
https://doaj.org/article/6bc59a5fcb344456893224aa55d49a65
Autor:
Hamied A. Haroon, Laura M. Parkes, Geoff J M Parker, G Castellazzi, Danka Jandric, Ilona Lipp, Valentina Tomassini, Nils Muhlert, David Rog, David Paling
Publikováno v:
Jandric, D, Lipp, I, Paling, D, Rog, D, Castellazzi, G, Haroon, H, Parkes, L, Parker, G J M, Tomassini, V & Muhlert, N 2021, ' Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis ', Neurology, vol. 97, no. 19, pp. E1886-E1897 . https://doi.org/10.1212/WNL.0000000000012834
Neurology
Neurology
Background and ObjectivesCognitive impairment in multiple sclerosis (MS) is associated with functional connectivity abnormalities. While there have been calls to use functional connectivity measures as biomarkers, there remains to be a full understan
Autor:
Carolyn A Young, Roger J Mills, Dawn Langdon, David J Rog, Basil Sharrack, Seema Kalra, Tahir Majeed, David Footit, Tim Harrower, Richard S Nicholas, Helen L Ford, John Woolmore, Clare Johnstone, John Thorpe, David Paling, Cathy Ellis, C Oliver Hanneman, Alan Tennant
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 28(14)
Background: Coping in multiple sclerosis (MS) refers to cognitive and behavioural efforts to manage stresses imposed by the illness. Existing generic and disease-specific coping scales do not meet modern guidelines for scale development and cannot pr
Autor:
Pamela J. Shaw, John P Franklin, James J.P. Alix, David Paling, Johnathan Cooper-Knock, Priya Shanmugarajah, Tobias Moll, Marios Hadjivissiliou, Nicholas J. Beauchamp, Christopher J McDermott, Michael Pattrick, Helia Ghahremani Nezhad, Thomas M Jenkins
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 22:579-582
Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) share a common molecular basis: both are associated with CAG-repeat expansion of ATXN2 and TDP-43-positive neuronal cytoplasmic inclusions. To date, the two disorders are vi
Autor:
Geoff J M Parker, Menno M. Schoonheim, David Paling, Richelle Scott, Danka Jandric, Nils Muhlert, David Rog, Anisha Doshi, Jeremy Chataway
Publikováno v:
Jandric, D, Doshi, A, Scott, R, Paling, D, Rog, D, Chataway, J, Schoonheim, M M, Parker, G & Muhlert, N 2022, ' A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis ', Brain Connectivity, vol. 12, no. 2, pp. 112-133 . https://doi.org/10.1089/brain.2021.0104
Jandric, D, Doshi, A, Scott, R, Paling, D, Rog, D, Chataway, J, Schoonheim, M, Parker, G & Muhlert, N 2021, ' A systematic review of resting state functional MRI connectivity changes and cognitive impairment in multiple sclerosis ', Brain Connectivity . https://doi.org/10.1089/brain.2021.0104
Jandric, D, Doshi, A, Scott, R, Paling, D, Rog, D, Chataway, J, Schoonheim, M, Parker, G & Muhlert, N 2021, ' A systematic review of resting state functional MRI connectivity changes and cognitive impairment in multiple sclerosis ', Brain Connectivity . https://doi.org/10.1089/brain.2021.0104
Introduction: Cognitive impairment in multiple sclerosis (MS) is increasingly being investigated with resting-state functional MRI (rs-fMRI) functional connectivity (FC). However, results remain difficult to interpret, showing both high and low FC as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9554576df39c1e3f1c72c0d46504517c
https://research.vumc.nl/en/publications/3b6a6fba-1344-406a-8cf8-54d6fc2653f1
https://research.vumc.nl/en/publications/3b6a6fba-1344-406a-8cf8-54d6fc2653f1
Autor:
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Gavin Giovannoni, Claudia Angela Gandini Wheeler-Kingshott, Clive Hawkins, Basil Sharrack, Roger Bastow, Christopher J Weir, Nigel Stallard, Siddharthan Chandran, Claudia A.M. Gandini Wheeler-Kingshott, Thomas Williams, Tiggy Beyene, Vanessa Bassan, Alvin Zapata, Dawn Lyle, James Cameron, Daisy Mollison, Shuna Colville, Baljean Dhillon, Christopher J. Weir, Richard A. Parker, Sharmilee Gnanapavan, Richard Nicholas, Waqar Rashid, Julia Aram, Helen Ford, James Overell, Carolyn Young, Heinke Arndt, Martin Duddy, Joe Guadagno, Nikolaos Evangelou, Matthew Craner, Jacqueline Palace, Jeremy Hobart, David Paling, Seema Kalra, Brendan McLean
Publikováno v:
Chataway, J, De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, Macmanus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J & Stallard, N & Chandran, S 2020, ' Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial ', The Lancet Neurology, vol. 19, no. 3, pp. 214-225 . https://doi.org/10.1016/S1474-4422(19)30485-5
O2, repositorio institucional de la UOC
Universitat Oberta de Catalunya (UOC)
Chataway, J, De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, MacManus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-Kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & MS-SMART Investigators 2020, ' Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial ', The Lancet Neurology, vol. 19, no. 3, pp. 214-225 . https://doi.org/10.1016/S1474-4422(19)30485-5
The Lancet Neurology, 19(3), 214-225. Lancet Publishing Group
O2, repositorio institucional de la UOC
Universitat Oberta de Catalunya (UOC)
Chataway, J, De Angelis, F, Connick, P, Parker, R A, Plantone, D, Doshi, A, John, N, Stutters, J, MacManus, D, Prados Carrasco, F, Barkhof, F, Ourselin, S, Braisher, M, Ross, M, Cranswick, G, Pavitt, S H, Giovannoni, G, Gandini Wheeler-Kingshott, C A, Hawkins, C, Sharrack, B, Bastow, R, Weir, C J, Stallard, N, Chandran, S & MS-SMART Investigators 2020, ' Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial ', The Lancet Neurology, vol. 19, no. 3, pp. 214-225 . https://doi.org/10.1016/S1474-4422(19)30485-5
The Lancet Neurology, 19(3), 214-225. Lancet Publishing Group
Background:\ud Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axona